Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.29 Insider Own42.60% Shs Outstand29.21M Perf Week-32.17%
Market Cap231.97M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float17.07M Perf Month21.31%
Income-37.37M PEG- EPS next Q- Inst Own5.11% Short Float6.18% Perf Quarter338.20%
Sales0.00M P/S- EPS this Y- Inst Trans-0.70% Short Ratio0.19 Perf Half Y766.67%
Book/sh0.20 P/B38.29 EPS next Y- ROA-75.90% Short Interest1.05M Perf Year406.49%
Cash/sh0.86 P/C9.02 EPS next 5Y- ROE-163.77% 52W Range0.66 - 14.30 Perf YTD430.61%
Dividend Est.- P/FCF- EPS past 5Y-46.75% ROI-222.80% 52W High-45.45% Beta-0.73
Dividend TTM- Quick Ratio2.00 Sales past 5Y-25.00% Gross Margin-3654.84% 52W Low1081.82% ATR (14)1.50
Dividend Ex-Date- Current Ratio2.00 EPS Y/Y TTM-39.34% Oper. Margin0.00% RSI (14)44.58 Volatility17.70% 16.14%
Employees42 Debt/Eq3.53 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price11.00
Option/ShortYes / Yes LT Debt/Eq1.80 EPS Q/Q7.40% Payout- Rel Volume0.93 Prev Close10.69
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMay 14 BMO Avg Volume5.54M Price7.80
SMA20-21.39% SMA5023.64% SMA200216.25% Trades Volume5,160,593 Change-27.03%
Date Action Analyst Rating Change Price Target Change
Dec-02-22Initiated H.C. Wainwright Buy $11
Nov-19-21Initiated BMO Capital Markets Outperform $18
Aug-23-21Initiated UBS Buy $9
Aug-23-21Initiated Jefferies Buy $22
Aug-23-21Initiated Credit Suisse Outperform $15
May-24-24 11:42AM
May-23-24 05:00PM
May-22-24 08:00AM
May-20-24 08:00AM
11:14AM Loading…
May-15-24 11:14AM
May-14-24 01:53PM
May-09-24 10:26AM
Apr-25-24 08:00AM
Apr-12-24 10:00AM
Apr-11-24 09:00AM
Apr-09-24 08:00AM
Apr-05-24 12:10PM
Apr-04-24 12:24PM
08:00AM Loading…
Mar-28-24 04:05PM
Mar-15-24 08:15AM
Mar-06-24 08:00AM
Mar-05-24 04:30PM
Feb-13-24 07:30AM
Feb-05-24 08:00AM
Dec-13-23 12:21PM
Dec-12-23 08:00AM
Nov-28-23 09:00AM
Nov-09-23 09:43AM
Nov-04-23 08:00AM
12:00PM Loading…
Nov-03-23 12:00PM
Oct-18-23 11:00AM
Sep-27-23 09:40AM
Sep-26-23 08:00AM
Sep-06-23 08:00AM
Aug-10-23 08:00AM
Aug-02-23 08:00AM
Jun-13-23 08:00AM
Jun-08-23 08:00AM
Jun-05-23 08:00AM
May-22-23 08:26AM
May-19-23 01:51PM
May-11-23 08:00AM
May-02-23 08:00AM
Apr-17-23 08:00AM
Mar-30-23 08:00AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 06:43AM
Feb-27-23 06:50AM
Feb-24-23 07:17AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
Feb-14-23 06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 08:00AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 07:00AM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
Jan-24-23 06:48AM
Jan-23-23 06:58AM
Jan-20-23 06:55AM
Jan-19-23 06:43AM
Jan-18-23 06:28AM
Jan-17-23 06:27AM
Jan-13-23 06:56AM
Jan-12-23 08:00AM
Jan-11-23 06:53AM
Jan-09-23 06:31AM
Jan-06-23 06:49AM
Jan-04-23 06:54AM
Jan-03-23 06:26AM
Dec-30-22 07:17AM
Dec-29-22 06:51AM
Dec-28-22 06:58AM
Dec-27-22 07:11AM
Dec-23-22 06:32AM
Dec-22-22 06:34AM
Dec-21-22 06:46AM
Dec-20-22 06:29AM
Candel Therapeutics, Inc. is a late clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.